Eagle Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Eagle Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,001,572	Closed	-$22.1M	–	641
2016 Q2	$22.1M	Buy	1,001,572 +7,747	+0.8%	+$203K	0.15%	192
2016 Q1	$29.2M	Sell	993,825 -102,239	-9%	-$2.85M	0.2%	155
2015 Q4	$36.2M	Buy	1,096,064 +41,619	+4%	+$1.36M	0.24%	145
2015 Q3	$38.1M	Sell	1,054,445 -293,383	-22%	-$12.6M	0.26%	130
2015 Q2	$60.6M	Buy	1,347,828 +220,590	+20%	+$8.58M	0.34%	106
2015 Q1	$34.5M	Buy	1,127,238 +17,594	+2%	+$685K	0.2%	166
2014 Q4	$56.4M	Buy	1,109,644 +183,771	+20%	+$8.23M	0.32%	108
2014 Q3	$36.6M	Buy	925,873 +123,514	+15%	+$4.92M	0.21%	160
2014 Q2	$34.6M	Buy	802,359 +273,016	+52%	+$10.4M	0.19%	170
2014 Q1	$21.2M	Buy	+529,343	New	+$19.2M	0.12%	238

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Eagle Asset Management's ENTA Position: Q3 2016 in Review

Eagle Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2016, closing a stake of 1,001,572 shares — an estimated $22.1M sold.

Eagle Asset Management first reported a position in ENTA in Q1 2014 and held it in 10 quarters. The position peaked at $60.6M in Q2 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q3 2016.

Eagle Asset Management reported no remaining Enanta Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Eagle Asset Management sold 1,001,572 Enanta Pharmaceuticals shares in Q3 2016, an estimated $22.1M.
Eagle Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Eagle Asset Management's Enanta Pharmaceuticals position peaked at $60.6M in Q2 2015.
136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2016.

Based on Eagle Asset Management's 13F filing for Q3 2016, filed 12 Oct 2016.